mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus.

Bringing together KOLs sharing case studies with actionable insights, the inaugural mRNA Process Development & Manufacturing Summit Europe has been established as the first forum in Europe to support your in-house process development and manufacturing strategies.

The 3-day agenda has been carefully co-authored along with the leaders within the industry from the likes of BioNTech, AstraZeneca and Genentech. A snapshot of key topics include:

1. Assessing how dsRNA formation can be limited to reduce the purification requirements of the manufacturing process with BioNTech SE
2. Uncovering how to maximise biocomparability when scaling up the batch manufacturing process, including identifying the critical process steps that introduce batch-to-batch variability with Genentech & Roche
3. A snapshot of robust, high-throughput online novel assays for identifying impurities with CureVac & AstraZeneca
4. Understanding critical quality attributes and the differences in process development considerations for mRNA therapeutics and vaccines to achieve appropriate drug substance quality with the University of Sheffield & University Hospital Zurich
5. Hearing how the global market could function with a standard process platform to benefit all patients with Medicines Patent Pool

This is an opportunity to join 80+ mRNA enthusiasts from mRNA manufacturing, analytics, process development, CMC, quality control, and drug substance to get key insights on scaling up mRNA drug substances in Europe whilst navigating mRNA process development and manufacturing regulatory guidelines to create commercially successful mRNA vaccines and therapeutics.

To know more visit: https://ter.li/f3ec38